These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16731025)

  • 61. Reducing uncertainty in value-based pricing using evidence development agreements: the case of continuous intraduodenal infusion of levodopa/carbidopa (Duodopa®) in Sweden.
    Willis M; Persson U; Zoellner Y; Gradl B
    Appl Health Econ Health Policy; 2010; 8(6):377-86. PubMed ID: 21043539
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease.
    Devos D;
    Mov Disord; 2009 May; 24(7):993-1000. PubMed ID: 19253412
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Body fat loss in patients with Parkinson's disease].
    Sakajiri K; Takamori M
    Rinsho Shinkeigaku; 1997 Jul; 37(7):611-4. PubMed ID: 9396358
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Long term bromocriptine treatment in de novo parkinsonian patients.
    Herskovits E; Yorio A; Leston J
    Medicina (B Aires); 1988; 48(4):345-50. PubMed ID: 3076200
    [No Abstract]   [Full Text] [Related]  

  • 66. [The use of amantadine sulfate in combined therapy of Parkinson's disease].
    Karaban' IN; Lukhanina EP; Kapustina MT; Karasevich NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(7):20-4. PubMed ID: 12161861
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The relationships between the unified Parkinson's disease rating scale and lower extremity functional performance in persons with early-stage Parkinson's disease.
    Song J; Fisher BE; Petzinger G; Wu A; Gordon J; Salem GJ
    Neurorehabil Neural Repair; 2009 Sep; 23(7):657-61. PubMed ID: 19336530
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience.
    Thomas I; Alam M; Bergquist F; Johansson D; Memedi M; Nyholm D; Westin J
    J Neurol; 2019 Mar; 266(3):651-658. PubMed ID: 30659356
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Treatment of parkinson disease with the combination of L-dopa (plus carbidopa) and trazodone].
    Piccinin GL; Piccirilli M; Agostini L
    Clin Ter; 1981 Mar; 96(6):621-6. PubMed ID: 7285527
    [No Abstract]   [Full Text] [Related]  

  • 70. Drug adherence in Parkinson's disease.
    Leopold NA; Polansky M; Hurka MR
    Mov Disord; 2004 May; 19(5):513-7. PubMed ID: 15133814
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study.
    García Ruiz PJ; Sesar Ignacio A; Ares Pensado B; Castro García A; Alonso Frech F; Alvarez López M; Arbelo González J; Baiges Octavio J; Burguera Hernández JA; Calopa Garriga M; Campos Blanco D; Castaño García B; Carballo Cordero M; Chacón Peña J; Espino Ibáñez A; Gorospe Onisalde A; Giménez-Roldán S; Granés Ibáñez P; Hernández Vara J; Ibáñez Alonso R; Jiménez Jiménez FJ; Krupinski J; Kulisevsky Bojarsky J; Legarda Ramírez I; Lezcano García E; Martínez-Castrillo JC; Mateo González D; Miquel Rodríguez F; Mir P; Muñoz Fargas E; Obeso Inchausti J; Olivares Romero J; Olivé Plana J; Otermin Vallejo P; Pascual Sedano B; Pérez de Colosía Rama V; Pérez López-Fraile I; Planas Comes A; Puente Periz V; Rodríguez Oroz MC; Sevillano García D; Solís Pérez P; Suárez Muñoz J; Vaamonde Gamo J; Valero Merino C; Valldeoriola Serra F; Velázquez Pérez JM; Yáñez Baña R; Zamarbide Capdepon I
    Mov Disord; 2008 Jun; 23(8):1130-6. PubMed ID: 18442107
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
    Antonini A; Tolosa E
    Expert Rev Neurother; 2009 Jun; 9(6):859-67. PubMed ID: 19496689
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2008 Jan; 61(1-2):42-8. PubMed ID: 18372774
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Globus pallidus stimulation in advanced Parkinson's disease.
    Rodrigues JP; Walters SE; Watson P; Stell R; Mastaglia FL
    J Clin Neurosci; 2007 Mar; 14(3):208-15. PubMed ID: 17150360
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion.
    Meiler B; Andrich J; Müller T
    Mov Disord; 2008 Jan; 23(1):145-6. PubMed ID: 17987653
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease.
    Piboolnurak P; Lang AE; Lozano AM; Miyasaki JM; Saint-Cyr JA; Poon YY; Hutchison WD; Dostrovsky JO; Moro E
    Mov Disord; 2007 May; 22(7):990-7. PubMed ID: 17443692
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
    Gerschlager W; Bloem BR
    Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
    [No Abstract]   [Full Text] [Related]  

  • 79. Early dopamine agonist treatment in Parkinson's disease.
    Rinne UK
    Adv Neurol; 1990; 53():417-9. PubMed ID: 1978520
    [No Abstract]   [Full Text] [Related]  

  • 80. Outcome of bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease: correlation with intra-operative multi-unit recordings but not with the type of anaesthesia.
    Lefaucheur JP; Gurruchaga JM; Pollin B; von Raison F; Mohsen N; Shin M; Ménard-Lefaucheur I; Oshino S; Kishima H; Fénelon G; Rémy P; Cesaro P; Gabriel I; Brugières P; Keravel Y; Nguyen JP
    Eur Neurol; 2008; 60(4):186-99. PubMed ID: 18667827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.